

# **Pharmacy Update**

Pharmacy Help Desk Phone Numbers (405)522-6205 option 4 or (800)522-0114 option 4
Service Hours: Monday – Friday (8:30a – 7:00p); Saturday (9:00a – 5:00p); Sunday (11:00a – 5:00p)
Email: <a href="mailto:pharmacy@okhca.org">pharmacy@okhca.org</a> OHCA Website: <a href="mailto:www.okhca.org">www.okhca.org</a>

PA Criteria: www.okhca.org/providers/rx/pa PA forms: www.okhca.org/rx-forms

February 24, 2012

# Multiple Sclerosis (MS) Medications Prior Authorization

Prior authorization requirements take effect March 7, 2012. Members who are currently taking these medications may continue therapy without prior authorization unless a gap in therapy is indicated in SoonerCare claims history.

## Tier 1 Interferons do not require prior authorization.

## **Tier 2 Interferons Prior Authorization Criteria:**

- 1. Documented diagnosis of relapsing remitting MS.
- 2. Tier-2 medications require failure of the preferred Tier-1 product defined as:
  - a. Occurrence of an exacerbation after 6 months.
  - b. Significant increase in MRI lesions after 6 months.
  - c. Adverse reactions or intolerable side effects.
- 3. No concurrent use with other therapies.
- 4. Compliance will be checked for continued approval every 6 months.

Tier 1	Tier 2
Interferon β - 1a ( <b>Rebif</b> ®)	Interferon β - 1a ( <b>Avonex</b> ®)
Interferon β - 1b ( <b>Betaseron</b> ®)	Interferon β - 1b (Extavia®)

### **Glatiramer Acetate (Copaxone®) Prior Authorization Criteria:**

- 1. FDA approved diagnosis.
- 2. No concurrent use with other therapies.
- 3. Compliance will be checked for continued approval every 6 months.

### Fingolimod (Gilenya®) Prior Authorization Criteria:

- 1. Documented diagnosis of relapsing remitting MS with at least one relapse in the previous 12 months, or transitioning from existing MS therapy.
- 2. No concurrent use with other therapies.
- 3. Compliance will be checked for continued approval every 6 months.

We appreciate the services you provide to Oklahomans insured by SoonerCare.